Cavrotolimod Designated Orphan Drug for Merkel Cell Carcinoma
Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
Melanoma
Melanoma News & Features
Reflectance Confocal Microscopy vs Biopsy for Diagnosis of Basal Cell Carcinoma
The sensitivity of reflectance confocal microscopy is evaluated in the context of basal cell carcinoma diagnosis.
Increased Incidence of Sebaceous Carcinoma Observed in Solid Organ Transplant Recipients
Population data was used to assess risk for sebaceous carcinoma and overall patient survival in the transplant population.
Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i.
AI Model May Predict Immunotherapy Response in Melanoma
Histology slides, clinical data used to predict immune checkpoint inhibitor response in advanced melanoma.
Melanoma Clinical Trials
Clinical Trial: Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Clinical Trial: Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma (Mel 51)
Clinical Trial: Study of Families With Melanoma
Clinical Trial: Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Clinical Trial: Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Melanoma
